

MARKET REPORT



UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylorthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Apr 16,2020: RDMD secures \$14 million in Series A Financing and announces partnership with UCB in Rare

<https://www.bioportfolio.co.uk/product/260230>
bioportfolio97@gmail.com to order

Neurodegenerative Disease

Feb 20,2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products

Dec 18,2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium

Oct 11,2019: UCB acquires Ra Pharma for \$2.1bn to enrich its rare disease portfolio

Oct 10,2019: UCB to acquire Ra Pharmaceuticals in \$2.1bn deal

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Additional Details

Publisher : Global Data

Reference :

Number of Pages : 63

Report Format : PDF

Publisher Information :

GlobalData»

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

- Table of Contents Table of Contents List of Tables List of Figures Section 1 - About the Company UCB SA - Key Facts UCB SA - Key Employees UCB SA - Key Employee Biographies UCB SA - Major Products and Services UCB SA - History UCB SA - Company Statement UCB SA - Locations And Subsidiaries Head Office Other Locations & Subsidiaries Joint Venture Section 2 - Company Analysis Company Overview UCB SA - Business Description Product Category: Established Brands Overview Performance Product Category: Immunology Overview Performance Product Category: Neurology Overview Performance Geographical Segment: Europe Target Markets Performance Geographical Segment: International Markets Performance Geographical Segment: The US Performance R&D Overview UCB SA - Corporate Strategy UCB SA - SWOT Analysis SWOT Analysis - Overview UCB SA - Strengths UCB SA - Weaknesses UCB SA - Opportunities UCB SA - Threats UCB SA - Key Competitors Section 3 - Company Financial Ratios Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts Section 4 - Company's Lifesciences Financial Deals and Alliances UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020 UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020 UCB SA, Recent Deals Summary Section 5 - Company's Recent Developments Apr 16, 2020: RDMD secures \$14 million in Series A Financing and announces partnership with UCB in Rare Neurodegenerative Disease Feb 20, 2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products Dec 18, 2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium Oct 11, 2019: UCB acquires Ra Pharma for \$2.1bn to enrich its rare disease portfolio Oct 10, 2019: UCB to acquire Ra Pharmaceuticals in \$2.1bn deal Aug 21, 2019: Global Biopharma Company UCB supports Cognitant Group to Deliver Visual and Interactive Health Information for Patients Jul 25, 2019: UCB's strong performance enables continued investment into future growth drivers Jul 02, 2019: DEARhealth announces collaboration with UCB to improve care delivery through new technology for patients living with epilepsy Jun 04, 2019: UCB Boston research is advancing medical innovation Mar 12, 2019: Ireland to lead €7 million Parkinson's research project Section 6 - Appendix Methodology Ratio Definitions About GlobalData Contact Us Disclaimer

List Of Tables in UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

List of Tables

UCB SA, Key Facts

UCB SA, Key Employees

UCB SA, Key Employee Biographies

UCB SA, Major Products and Services

UCB SA, History

UCB SA, Subsidiaries

UCB SA, Joint Venture

UCB SA, Key Competitors

UCB SA, Ratios based on current share price

UCB SA, Annual Ratios

UCB SA, Annual Ratios (Cont...1)

UCB SA, Annual Ratios (Cont...2)

UCB SA, Interim Ratios

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

UCB SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List Of Figures, Charts and Diagrams in UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

List of Figures

UCB SA, Performance Chart (2015 - 2019)

UCB SA, Ratio Charts

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

How to Buy...

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/260230>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$106** | Single User Price
- \$213** | Site License Price
- \$319** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.